Topical administration of tranexamic acid in total hip arthroplasty: A meta-analysis of Randomized Controlled Trials

• Published in: Drug Discoveries & Therapeutics Vol. 9; no. 3; pp. 173 - 177
• Main Authors: Xu, Xingming, Xiong, Shan, Wang, Zhenyu, Li, Xiaofeng, Liu, Wei
• Format: Journal Article
• Language: English
• Published: Japan International Research and Cooperation Association for Bio & Socio-Sciences Advancement 01.06.2015
• Subjects: Administration, Topical; Antifibrinolytic Agents - administration & dosage; Arthroplasty, Replacement, Hip; Humans; intra-articular; meta-analysis; Topical administration; total hip arthroplasty; tranexamic acid; Tranexamic Acid - administration & dosage; Tranexamic Acid - adverse effects
• ISSN: 1881-7831; 1881-784X
• DOI: 10.5582/ddt.2015.01018

Tranexamic acid (TXA) is an antifibrinolytic drug which has been widely used in many areas of surgery. The purpose of our meta-analysis was to review randomized controlled trials (RCT) of the effectiveness and safety of topical TXA treatment in reducing total blood loss and transfusion rate for patients undergoing primary total hip arthroplasty (THA). A literature search was undertaken. Five eligible reports match the inclusion and exclusion standard. The topical administration of TXA groups revealed lower total blood loss(mean difference - 347ml, 95% CI, - 411 to - 282 mL; p < 0.00001) and transfusion rate (OR, 0.23 (p < 0.00001; 95% CI, 0.14-0.38)) compared with control groups. Meanwhile there was no statistically significant difference in the risk of developing thromboembolic events (OR, 1.64 (95% CI, 0.39-6.97); p = 0.5). Topical administration of TXA could significantly reduce total blood loss and transfusion requirements in primary THA, without increased thromboembolic complications.